However, the use of AhR agonists as anticancer agents against breast cancer may lead to the down-regulation of SLCOs, and, therefore, the combination with OATP/SLCO substrate drugs should be investigated thoroughly. This evidence concerns the gene SLCO1A2 and breast cancer.